Quantum Private Wealth LLC Buys 64,140 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Quantum Private Wealth LLC increased its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 11.1% during the fourth quarter, Holdings Channel reports. The firm owned 639,520 shares of the company’s stock after acquiring an additional 64,140 shares during the period. Quantum Private Wealth LLC’s holdings in Taysha Gene Therapies were worth $1,132,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of TSHA. Howard Capital Management Inc. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth $25,000. Capital Investment Advisors LLC bought a new position in Taysha Gene Therapies in the third quarter valued at about $32,000. Maven Securities LTD bought a new position in Taysha Gene Therapies in the fourth quarter valued at about $34,000. China Universal Asset Management Co. Ltd. bought a new position in Taysha Gene Therapies in the fourth quarter valued at about $38,000. Finally, AQR Capital Management LLC bought a new position in Taysha Gene Therapies in the second quarter valued at about $38,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 2.7 %

Shares of Taysha Gene Therapies stock traded down $0.07 during midday trading on Wednesday, reaching $2.51. The company had a trading volume of 445,227 shares, compared to its average volume of 2,665,923. The stock has a fifty day moving average price of $2.51 and a 200 day moving average price of $2.10. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. Taysha Gene Therapies, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.39 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on TSHA. Canaccord Genuity Group reiterated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Needham & Company LLC reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 11th. Piper Sandler started coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target on the stock. Chardan Capital lifted their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $6.88.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.